Abstract 247P
Background
Adenocarcinoma is an uncommon histologic variant and accounts for 0.5-2% of bladder cancers in the United States. Due to its rarity, there is limited data in the literature specifically focused on bladder adenocarcinoma treatment. So, the aim of this study is focused on evaluating the impact of chemoradiotherapy compared to multiple treatment modalities on the survival of patients with primary bladder adenocarcinoma.
Methods
The Surveillance, Epidemiology, and End Results (SEER) Program 17 registries database was utilized to identify primary bladder adenocarcinoma cases from (2000-2020). The disease stages and sociodemographic data were collected. The patients were subgrouped according to the treatment modality: primary chemotherapy, surgery only, adjuvant chemotherapy, adjuvant radiotherapy, and adjuvant chemoradiotherapy. SPSS Version 23 was used for data analysis. log-rank Kaplan-Meir curve was used for survival analysis.
Results
A total of 2500 cases of bladder adenocarcinoma were identified. Overall, the 5-year relative survival was 43.1%. With multiple treatment options, we found surgery with no systemic therapy had a better survival outcome (47.4%) compared to adjuvant chemotherapy (38%), adjuvant chemoradiotherapy (31.4), adjuvant radiotherapy (21.5%), and least primary chemotherapy (4.9%) (P <0.001). In the group that had surgical management with no systemic therapy, the localized stage had significantly improved survival compared to the regional and distant spread (62%, 40%, and 10.8%, respectively; P <0.001).
Conclusions
This study provides a comprehensive evaluation of multiple treatment modalities, and the results highlight surgery with no systemic therapy as the modality of choice for improved survival outcome. This eliminates the burden of adjuvant therapy with unfavorable side effects. However, few selected patients may use chemo(radio)therapy with special considerations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract